NanoViricides Reports Promising Antiviral Drug NV-387 in Clinical Trials

NanoViricides, Inc., a clinical-stage company, announced that its antiviral drug NV-387, designed using host-mimetic nanomedicine technology, has advanced into Phase II clinical trials. The drug aims to mitigate metastatic cancer resurgence linked to viral infections. Recent studies show viral infections causing inflammation, especially involving cytokine IL-6, may awaken dormant cancer cells, increasing metastatic cancer risks.

NV-387 not only targets viruses but also reduces inflammation, thereby potentially preventing the reactivation of dormant cancer cells. The drug successfully reduced IL-6 levels in animal models, with lung protection demonstrated in studies involving RSV and Influenza A/H3N2, highlighting its potential clinical efficacy where other treatments, like Tamiflu, failed.

Globally endemic viruses, including COVID-19 and Influenza, pose significant health challenges due to their potential to trigger cancer recurrence. NV-387's efficacy across multiple viruses highlights its importance amid ever-changing viral variants, which often render antibodies and vaccines less effective.